A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants

Hong Tang(Coherus BioSciences (United States)), Barbara Finck(Coherus BioSciences (United States)), Suzanna Tatarewicz(Coherus BioSciences (United States)), Francesca Civoli(Coherus BioSciences (United States)), Nathalie Vandenkoornhuyse(Coherus BioSciences (United States))
Advances in Therapy
January 5, 2024
Cited by 3


Related Papers